Symptoms compatible with long COVID in an Italian pediatric cohort of Tourette patients with and without SARS‑CoV‑2 infection: a short-term follow-up assessment.
COVID-19
Children
Long COVID
Mental health
Pandemic
Pediatrics
Tourette Syndrome
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
05 05 2023
05 05 2023
Historique:
received:
25
01
2023
accepted:
26
04
2023
medline:
8
5
2023
pubmed:
6
5
2023
entrez:
5
5
2023
Statut:
epublish
Résumé
Tourette Syndrome (TS) is a childhood-onset neurodevelopmental disorder with a worldwide prevalence of about 0.3-1% of the population. During the pandemic caused by SARS-CoV-2 infection, the impact on the mental health of children and adolescents was very important. The persistence of symptoms in the post-acute phase of the disease has been termed Long COVID. The neuropsychiatric symptoms seem to be the most common impairment in children and adolescents with long COVID. Considering the impact of pandemic on mental health, in this study we analyzed the long-term effects of SARS-CoV-2 infection in children and adolescents affected by TS. We conducted an online questionnaire covering socio-demographic and clinical data among 158 patients affected by TS or chronic tic disorders (CTD), of which 78 participants reported a positive SARS-CoV-2 infection. Data were collected to investigate tic severity and both the comorbidities, as well as lockdown-related changes to daily life activities and, in case of infection of SARS-CoV-2, possible symptoms of acute infection and long COVID. Markers of systemic inflammation including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, iron, electrolytes, white blood cell counts, platelet cell counts levels, markers of liver, kidney and thyroid function were analyzed. First, all patients were screened with the Schedule for affective disorders and Schizophrenia for School age children-present and lifetime (Kiddie-SADS-PL) to rule out primary psychiatric disorders considered as criteria of exclusion. Then, all patients were clinically assessed at baseline (T0), and after three months (T1) through the administration of Yale Global Tic Severity Rating Scale (YGTSS), Multidimensional Anxiety Scale for Children (MASC), Child Depression Inventory (CDI) and Child Behavior Checklist (CBCL). Among the cohort of TS patients that contracted SARS-CoV-2 infection, 84.6% (n = 66) experienced any acute symptoms, and long COVID symptoms occurred in 38.5% (n = 30). A worsening of clinical symptoms of tics and eventually associated comorbidities occurred in 34.6% (n = 27) of TS patients that contracted SARS-CoV-2 infection. TS patients with or without SARS-CoV-2 infection showed an increase in the severity of tics and also behavioral, depressive and anxious symptoms. Instead, this increase was more evident in patients who contracted the infection than in patients who did not contract it. SARS-CoV-2 infection may have a role in the increase of tics and associated comorbidities in TS patients. Despite of these preliminary results, further investigations are necessary to improve knowledge about the acute and long-term impact of SARS-CoV-2 in TS patients.
Sections du résumé
BACKGROUND
Tourette Syndrome (TS) is a childhood-onset neurodevelopmental disorder with a worldwide prevalence of about 0.3-1% of the population. During the pandemic caused by SARS-CoV-2 infection, the impact on the mental health of children and adolescents was very important. The persistence of symptoms in the post-acute phase of the disease has been termed Long COVID. The neuropsychiatric symptoms seem to be the most common impairment in children and adolescents with long COVID.
OBJECTIVES
Considering the impact of pandemic on mental health, in this study we analyzed the long-term effects of SARS-CoV-2 infection in children and adolescents affected by TS.
METHODS
We conducted an online questionnaire covering socio-demographic and clinical data among 158 patients affected by TS or chronic tic disorders (CTD), of which 78 participants reported a positive SARS-CoV-2 infection. Data were collected to investigate tic severity and both the comorbidities, as well as lockdown-related changes to daily life activities and, in case of infection of SARS-CoV-2, possible symptoms of acute infection and long COVID. Markers of systemic inflammation including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, iron, electrolytes, white blood cell counts, platelet cell counts levels, markers of liver, kidney and thyroid function were analyzed. First, all patients were screened with the Schedule for affective disorders and Schizophrenia for School age children-present and lifetime (Kiddie-SADS-PL) to rule out primary psychiatric disorders considered as criteria of exclusion. Then, all patients were clinically assessed at baseline (T0), and after three months (T1) through the administration of Yale Global Tic Severity Rating Scale (YGTSS), Multidimensional Anxiety Scale for Children (MASC), Child Depression Inventory (CDI) and Child Behavior Checklist (CBCL).
RESULTS
Among the cohort of TS patients that contracted SARS-CoV-2 infection, 84.6% (n = 66) experienced any acute symptoms, and long COVID symptoms occurred in 38.5% (n = 30). A worsening of clinical symptoms of tics and eventually associated comorbidities occurred in 34.6% (n = 27) of TS patients that contracted SARS-CoV-2 infection. TS patients with or without SARS-CoV-2 infection showed an increase in the severity of tics and also behavioral, depressive and anxious symptoms. Instead, this increase was more evident in patients who contracted the infection than in patients who did not contract it.
CONCLUSIONS
SARS-CoV-2 infection may have a role in the increase of tics and associated comorbidities in TS patients. Despite of these preliminary results, further investigations are necessary to improve knowledge about the acute and long-term impact of SARS-CoV-2 in TS patients.
Identifiants
pubmed: 37147589
doi: 10.1186/s12887-023-04035-9
pii: 10.1186/s12887-023-04035-9
pmc: PMC10161986
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222Informations de copyright
© 2023. The Author(s).
Références
World J Psychiatry. 2021 Jul 19;11(7):347-354
pubmed: 34327127
Arch Dis Child. 2022 Jul;107(7):674-680
pubmed: 35365499
Psychiatry Res. 2020 Nov;293:113429
pubmed: 32882598
World J Pediatr. 2021 Oct;17(5):495-499
pubmed: 34478045
Front Neurol. 2020 Sep 16;11:567407
pubmed: 33041996
Br J Psychiatry. 2020 Mar;216(3):159-162
pubmed: 31718718
Lancet Child Adolesc Health. 2021 Jun;5(6):e19-e21
pubmed: 33961798
Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487
pubmed: 34870392
J Obsessive Compuls Relat Disord. 2014 Oct;3(4):372-379
pubmed: 30197854
Int J Environ Res Public Health. 2021 Mar 26;18(7):
pubmed: 33810225
Front Psychiatry. 2020 Nov 30;11:583744
pubmed: 33329125
Curr Pediatr Rep. 2022;10(2):31-44
pubmed: 35287333
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Brain Sci. 2022 Apr 19;12(5):
pubmed: 35624901
Can Fam Physician. 2022 Apr;68(4):263-265
pubmed: 35418390
JAMA Pediatr. 2021 Nov 1;175(11):1142-1150
pubmed: 34369987
Continuum (Minneap Minn). 2019 Aug;25(4):936-958
pubmed: 31356288
Front Neurosci. 2022 Dec 15;16:999346
pubmed: 36590292
Neurol Sci. 2022 Jun;43(6):3497-3501
pubmed: 35275319
Arch Dis Child. 2021 Mar 6;:
pubmed: 33677431
Front Microbiol. 2021 Jun 23;12:698169
pubmed: 34248921
Int J Mol Sci. 2021 Jan 16;22(2):
pubmed: 33467014
Int J Environ Res Public Health. 2021 Sep 19;18(18):
pubmed: 34574803
Clin Exp Neuroimmunol. 2022 Feb;13(1):17-23
pubmed: 34899999
Child Psychiatry Hum Dev. 2022 Apr 13;:
pubmed: 35416566
Neuropsychiatr Dis Treat. 2021 Sep 24;17:3007-3014
pubmed: 34594104
Behav Modif. 2014 Mar;38(2):184-216
pubmed: 24516255
J Am Acad Child Adolesc Psychiatry. 1997 Apr;36(4):554-65
pubmed: 9100431
Neurol Sci. 2020 Oct;41(10):2657-2669
pubmed: 32725449
Future Microbiol. 2022 May;17:577-588
pubmed: 35360923
Biol Psychiatry. 2016 Mar 1;79(5):372-382
pubmed: 25199956
JAMA Psychiatry. 2015 Apr;72(4):325-33
pubmed: 25671412
Curr Pediatr Rep. 2022;10(1):11-17
pubmed: 35127274
Mov Disord Clin Pract. 2020 Jul 03;7(6):725-726
pubmed: 32775530
Epilepsy Behav. 2021 Feb;115:107519
pubmed: 33257293
Front Psychiatry. 2022 May 24;13:862422
pubmed: 35686189
J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73
pubmed: 2768151
Life (Basel). 2022 Feb 14;12(2):
pubmed: 35207572
Ital J Pediatr. 2022 Mar 9;48(1):42
pubmed: 35264214
Curr Pediatr Rep. 2021;9(4):83-92
pubmed: 34692237
Ital J Pediatr. 2022 May 21;48(1):79
pubmed: 35598023